Pharmaceutical Executive
Ambien CR, the sleep medication that "helps you fall asleep fast and stay asleep" caught the eyes (and ears!) of consumers with, well, a rooster.
SILENCE YOUR ROOSTER
Saatchi & Saatchi Consumer Health + Wellness
BRAND Ambien CR CLIENT Sanofi-Aventis FROM LEFT: Andrew Curtis, copywriter; Jay Marrotte, art director
Ambien CR, the sleep medication that "helps you fall asleep fast and stay asleep" caught the eyes (and ears!) of consumers with, well, a rooster.
"The need for something that was symbolic came from the client," says Sergio Flores, associate creative director of Saatchi & Saatchi Healthcare. "We thought it would be interesting to take something that represents morning—a rooster—and have it come in the middle of the night."
DTC Ranking: Here's the year's most memorable advertising (Score based on recall 24 hours after viewing; 120=very strong)
A rooster (specially trained to stay up at night) assaults viewers with a series of antics—playing basketball, beating on drums, vacuuming—that gets consumers' attention by making them laugh. The 15-second spots, which mirror the myriad annoyances that keep people from falling or staying asleep, strike a personal chord: Whether it's worrying about a job, paying bills, etc., everyone has their own "rooster."
The spot teases consumers to visit Ambien CR's microsite, SilenceYourRooster.com. "We wanted to do it absurd, and blind enough so there'd be a better chance of getting people to go online," says Andrew Curtis, copywriter. "We wanted to create enough buzz and word of mouth to drive people to the branded microsite." In its first two weeks, the site received more than a million hits.
Roche Inks Deal to Acquire Poseida Therapeutics
December 2nd 2024Under terms of the deal, Roche will gain access to Poseida’s pipeline, including P-BCMA-ALLO1, an allogeneic CAR T-cell therapy for multiple myeloma, and P-CD19CD20-ALLO1, a dual CAR T-cell therapy in early trials for B-cell malignancies and autoimmune diseases.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.